Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy in Resectable NSCLC
NCT00273507Phase 3Terminated
- Sponsor
- Rigshospitalet
- Start
- Jan 1998
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Overall Survival. Started Jan 1998; status: terminated.
02
Drugs
carboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00273507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273507.